Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men

Journal of Infectious Diseases

Volumn 202, Issue 8, 2010, Pages 1246-1253

  Wilkin, Timothy ^a   Lee, Jeannette Y ^c   Lensing, Shelly Y ^c   Stier, Elizabeth A ^d   Goldstone, Stephen E ^a   Berry, J Michael ^e   Jay, Naomi ^e   Aboulafia, David ^g,h   Cohn, David L ⁱ   Einstein, Mark H ^a,b   Saah, Alfred ^j   Mitsuyasu, Ronald T ^f   Palefsky, Joel M ^e  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g VIRGINIA MASON MEDICAL CENTER   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j Merck   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS RNA; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18; VIRUS ANTIBODY;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; SEROCONVERSION; TINNITUS; VACCINATION; ANAL CANAL; ANUS TUMOR; BLOOD; CYTOLOGY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; STANDARD; VIROLOGY;

ADULT; ANAL CANAL; ANTIBODIES, VIRAL; ANUS NEOPLASMS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRUS VACCINES;

EID: 77956984657     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/656320     Document Type: Article

References (27)

1. Zaki SR, Judd R, Coffield LM, Greer P, Rolston F, Evatt BL. Human papillomavirus infection and anal carcinoma. retrospective analysis by in situ hybridization and the polymerase chain reaction. Am J Pathol 1992; 140(6):1345-1355.
2. Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009; 124(10):2375-2383.
3. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998; 351(9119):1833-1839.
4. Bower M, Powles T, Newsom-Davis T, et al. HIV-associated anal cancer: Has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr 2004; 37(5):1563-1565.
5. Diamond C, Taylor TH, Aboumrad T, Bringman D, Anton-Culver H. Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. Sex Transm Dis 2005; 32(5):314-320. (Pubitemid 40578072)
6. D'Souza G, Wiley DJ, Li X, et al. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2008; 48(4):491-499.
7. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148(10):728-736.
8. Piketty C, Selinger-Leneman H, Grabar S, et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 2008; 22(10):1203-1211.
9. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis 2002; 35(9):1127-1134.
10. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356(19):1928-1943. (Pubitemid 46740303)
11. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356(19):1915-1927. (Pubitemid 46740302)
12. Palefsky J, Giuliano A. Quadrivalent vaccine efficacy in men having sex with men. In: Program and abstracts of the 25th International Papillomavirus Conference. Birmingham, AL: International Papillomavirus Society, 2009. Abstract O27.01.
13. Gardasil package insert. http://www.merck.com/product/usa/pi-circulars/g/ gardasil/gardasil-pi.pdf. Accessed 29 January 2010.
14. Shire NJ, Welge JA, Sherman KE. Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: A hierarchical bayesian meta-analysis. Vaccine 2006; 24(3):272-279.
15. Overton ET, Sungkanuparph S, Powderly WG, Seyfried W, Groger RK, Aberg JA. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005; 41(7):1045-1048. (Pubitemid 41368231)
16. Kim HN, Harrington RD, Crane HM, Dhanireddy S, Dellit TH, Spach DH. Hepatitis B vaccination in HIV-infected adults: Current evidence, recommendations and practical considerations. Int J STD AIDS 2009; 20(9):595-600.
17. Common terminology criteria for adverse events v3.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3. pdf. Accessed 29 January 2010.
18. Jay N, Berry JM, Hogeboom CJ, Holly EA, Darragh TM, Palefsky JM. Colposcopic appearance of anal squamous intraepithelial lesions: Relationship to histopathology. Dis Colon Rectum 1997; 40(8):919-928. (Pubitemid 27355394)
19. Reid R, Stanhope CR, Herschman BR, Crum CP, Agronow SJ. Genital warts and cervical cancer. IV. A colposcopic index for differentiating subclinical papillomaviral infection from cervical intraepithelial neoplasia. Am J Obstet Gynecol 1984; 149(8):815-823. (Pubitemid 14057200)
20. Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 1998; 177(2):361-367. (Pubitemid 28063760)
21. Morrison EA, Goldberg GL, Kadish AS, Burk RD. Polymerase chain reaction detection of human papillomavirus: Quantitation may improve clinical utility. J Clin Microbiol 1992; 30(10):2539-2543.
22. Opalka D, Lachman CE, MacMullen SA, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003; 10(1):108-115.
23. Dias D, Van Doren J, Schlottmann S, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 2005; 12(8):959-969.
24. Hagensee ME, Kiviat N, Critchlow CW, et al. Seroprevalence of human papillomavirus types 6 and 16 capsid antibodies in homosexual men. J Infect Dis 1997; 176(3):625-631. (Pubitemid 27360525)
25. Hopfl R, Petter A, Thaler P, Sarcletti M, Widschwendter A, Zangerle R. High prevalence of high risk human papillomavirus-capsid antibodies in human immunodeficiency virus-seropositive men: a serological study. BMC Infect Dis 2003; 3:6. (Pubitemid 38671464)
26. Munoz N, Manalastas R,Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009; 373(9679):1949-1957.
27. Clinical review of biologics license application supplement STN# 125126/1297.0- male indication for GARDASIL, table 20, page 40. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ UCM190977.pdf. Accessed 29 January 2010.